Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Accumulated Expenses: 2022-2025

Historic Accumulated Expenses for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $490,405.

  • InMed Pharmaceuticals' Accumulated Expenses rose 15.03% to $274,250 in Q3 2025 from the same period last year, while for Sep 2025 it was $274,250, marking a year-over-year increase of 15.03%. This contributed to the annual value of $490,405 for FY2025, which is 0.44% up from last year.
  • InMed Pharmaceuticals' Accumulated Expenses amounted to $490,405 in FY2025, which was up 0.44% from $488,278 recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' Accumulated Expenses ranged from a high of $839,638 in FY2022 and a low of $488,278 during FY2024.
  • Moreover, its 3-year median value for Accumulated Expenses was $490,405 (2025), whereas its average is $506,996.
  • In the last 5 years, InMed Pharmaceuticals' Accumulated Expenses crashed by 35.41% in 2023 and then rose by 0.44% in 2025.
  • InMed Pharmaceuticals' Accumulated Expenses (Yearly) stood at $839,638 in 2022, then slumped by 35.41% to $542,305 in 2023, then fell by 9.96% to $488,278 in 2024, then climbed by 0.44% to $490,405 in 2025.